CHELI, STEFANIA
CHELI, STEFANIA
Universita' degli Studi di MILANO
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort
2025 M. Schiuma, S. Dinegro, V. Battini, A. Torre, A. Covizzi, A. Civati, M. Galimberti, I. Mariani, G. Mosini, C. Carnovale, A. Riva, A. Gori, S. Antinori, E. Clementi, S. Radice, S. Cheli
Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults
2024 G. Cirnigliaro, V. Battini, M. Castiglioni, M. Renne, G. Mosini, S. Cheli, C. Carnovale, B. Dell'Osso
NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study
2024 S. Cheli, A. Torre, M. Schiuma, C. Montrasio, A. Civati, M. Galimberti, V. Battini, I. Mariani, G. Mosini, C. Carnovale, S. Radice, E. Clementi, A. Gori, S. Antinori
Pharmacogenetic Practice of Anticancer Drugs: Multiple Approaches for an Accurate and Comprehensive Genotyping
2023 C. Montrasio, S. Cheli, E. Clementi
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients
2021 S. Demurtas, N. La Verde, S. Rota, G. Casazza, C. Montrasio, S. Cheli, M.S. Cona, D. Dalu, C. Fasola, S. Ferrario, V. Filipazzi, A. Gambaro, N. Tosca, E. Clementi
In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5
2021 S. Cheli, M. Fusi, A. De Silvestri, I. Bonini, E. Clementi, D. Cattaneo, C. Montrasio, S. Baldelli
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment
2021 S. Cheli, S. Baldelli, A. De Silvestri, M. Fusi, D. Minisci, C. Gervasoni, D. Cattaneo, E. Clementi, P. Meraviglia, C. Montrasio
Different effects of glucocorticoids on darunavir plasma concentrations
2019 D. Cattaneo, S. Cheli, M. Fusi, E. Clementi, C. Gervasoni
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
2019 F. Nichetti, F.S. Falvella, R. Miceli, S. Cheli, R. Gaetano, G. Fucà, G. Infante, A. Martinetti, C. Antoniotti, A. Falcone, M. Di Bartolomeo, C. Cremolini, F. de Braud, F. Pietrantonio
Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure
2019 S. Corti, P. Pileri, M.I. Mazzocco, C. Mando', A.F. Moscatiello, D. Cattaneo, S. Cheli, S. Baldelli, P. Laura, E.G.I. Clementi, I. Cetin
Clinical and genetic determinants of nevirapine plasma trough concentration
2018 A. Giacomelli, S. Rusconi, F.S. Falvella, M.L. Oreni, D. Cattaneo, V. Cozzi, G. Renisi, E. Monge, S. Cheli, E. Clementi, A. Riva, M. Galli, A.L. Ridolfo
The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression : a case report
2017 S. Antoniazzi, A. Tatulli, F.S. Falvella, M. Cigliobianco, R.A. Paoli, D. Cattaneo, S. Cheli, F.F. Bernardi, E. Clementi, C.A. Altamura
Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting
2017 L. Milazzo, C. Gervasoni, F.S. Falvella, D. Cattaneo, C. Mazzali, P. Ronzi, F. Binda, S. Cheli, S. Sollima, S. Antinori
HLA-B*57: 01 testing : Care in interpreting the quality of different genotyping methods
2017 F.S. Falvella, S. Cheli, E. Clementi
The role of Toll-like receptor 4 polymorphisms in vaccine immune response
2016 P. Pellegrino, F.S. Falvella, S. Cheli, C. Perrotta, E. Clementi, S. Radice
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab
2016 F.S. Falvella, C. Cremolini, R. Miceli, F. Nichetti, S. Cheli, C. Antoniotti, G. Infante, A. Martinetti, F. Marmorino, E. Sottotetti, R. Berenato, M. Caporale, A. Colombo, F. de Braud, M. Di Bartolomeo, E. Clementi, F. Loupakis, F. Pietrantonio
Pharmacogenetic approach to losartan in Marfan patients : A starting point to improve dosing regimen?
2016 F.S. Falvella, S. Marelli, S. Cheli, S. Montanelli, F. Viecca, L. Salvi, A. Ferrara, E. Clementi, G. Trifirò, A. Pini
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
2015 F.S. Falvella, S. Cheli, A. Martinetti, C. Mazzali, R. Iacovelli, C. Maggi, M. Gariboldi, M.A. Pierotti, M. Di Bartolomeo, E. Sottotetti, R. Mennitto, I. Bossi, F. de Braud, E. Clementi, F. Pietrantonio
LightSNiP assay is a good strategy for pharmacogenetics test
2015 S. Cheli, F. Pietrantonio, E. Clementi, F.S. Falvella
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase
2015 F.S. Falvella, M. Caporale, S. Cheli, A. Martinetti, R. Berenato, C. Maggi, M. Niger, F. Ricchini, I. Bossi, M. Di Bartolomeo, E. Sottotetti, F.F. Bernardi, F. de Braud, E. Clementi, F. Pietrantonio